Biohaven's Kv7 Program Remains Key Stock Driver, UBS Says

MT Newswires Live09-18

Biohaven's (BHVN) stock performance is likely to remain focused on the outlook for its Kv7 program as the company navigates regulatory uncertainty around BHV-7000, while upcoming obesity data in H2 is expected to be a secondary catalyst, UBS Securities said in a note.

The firm said the largest potential driver of stock upside is Biohaven's degrader program in generalized dystonia and IgA nephropathy.

UBS remains confident the degraders could differentiate from competition, but noted that the primary completion dates are January 2028 for generalized dystonia and September 2028 for IgA nephropathy.

The firm also noted Biohaven's partial clinical hold on BHV-7000 requires additional nonclinical studies related to a metabolite observed in rodents and pauses enrollment in the RISE-2 study. The partial hold does not affect RISE-3, which is fully enrolled, with UBS expecting data in November.

UBS reiterated its neutral rating and $11 price target on Biohaven.

Price: 13.99, Change: +0.10, Percent Change: +0.72

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2668922511?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-18 23:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2668922511","market":"hk","top_or_hot":-1,"title":"Biohaven's Kv7 Program Remains Key Stock Driver, UBS Says","media":"MT Newswires Live","content":"<html><body><p> Biohaven's (BHVN) stock performance is likely to remain focused on the outlook for its Kv7 program as the company navigates regulatory uncertainty around BHV-7000, while upcoming obesity data in H2 is expected to be a secondary catalyst, UBS Securities said in a note.</p><p>The firm said the largest potential driver of stock upside is Biohaven's degrader program in generalized dystonia and IgA nephropathy.</p><p>UBS remains confident the degraders could differentiate from competition, but noted that the primary completion dates are January 2028 for generalized dystonia and September 2028 for IgA nephropathy.</p><p>The firm also noted Biohaven's partial clinical hold on BHV-7000 requires additional nonclinical studies related to a metabolite observed in rodents and pauses enrollment in the RISE-2 study. The partial hold does not affect RISE-3, which is fully enrolled, with UBS expecting data in November.</p><p>UBS reiterated its neutral rating and $11 price target on Biohaven.</p><p>Price: 13.99, Change: +0.10, Percent Change: +0.72</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biohaven's Kv7 Program Remains Key Stock Driver, UBS Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiohaven's Kv7 Program Remains Key Stock Driver, UBS Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-09-18 23:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Biohaven's (BHVN) stock performance is likely to remain focused on the outlook for its Kv7 program as the company navigates regulatory uncertainty around BHV-7000, while upcoming obesity data in H2 is expected to be a secondary catalyst, UBS Securities said in a note.</p><p>The firm said the largest potential driver of stock upside is Biohaven's degrader program in generalized dystonia and IgA nephropathy.</p><p>UBS remains confident the degraders could differentiate from competition, but noted that the primary completion dates are January 2028 for generalized dystonia and September 2028 for IgA nephropathy.</p><p>The firm also noted Biohaven's partial clinical hold on BHV-7000 requires additional nonclinical studies related to a metabolite observed in rodents and pauses enrollment in the RISE-2 study. The partial hold does not affect RISE-3, which is fully enrolled, with UBS expecting data in November.</p><p>UBS reiterated its neutral rating and $11 price target on Biohaven.</p><p>Price: 13.99, Change: +0.10, Percent Change: +0.72</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2668922511","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2668922511","pubTimestamp":1789746396,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Biohaven's  stock performance is likely to remain focused on the outlook for its Kv7 program as the company navigates regulatory uncertainty around BHV-7000, while upcoming obesity data in H2 is expected to be a secondary catalyst, UBS Securities said in a note.The firm said the largest potential driver of stock upside is Biohaven's degrader program in generalized dystonia and IgA nephropathy.UBS remains confident the degraders could differentiate from competition, but noted that the primary completion dates are January 2028 for generalized dystonia and September 2028 for IgA nephropathy.The firm also noted Biohaven's partial clinical hold on BHV-7000 requires additional nonclinical studies related to a metabolite observed in rodents and pauses enrollment in the RISE-2 study. The partial hold does not affect RISE-3, which is fully enrolled, with UBS expecting data in November.UBS reiterated its neutral rating and $11 price target on Biohaven.Price: 13.99, Change: +0.10, Percent Change:","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BHVN":"Biohaven Pharmaceutical Holding Co Ltd.","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1"},"translate_title":"瑞银表示，Biohaven 的 Kv7 计划仍然是主要股票驱动因素","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BHVN":1},"content_text":"Biohaven's (BHVN) stock performance is likely to remain focused on the outlook for its Kv7 program as the company navigates regulatory uncertainty around BHV-7000, while upcoming obesity data in H2 is expected to be a secondary catalyst, UBS Securities said in a note.The firm said the largest potential driver of stock upside is Biohaven's degrader program in generalized dystonia and IgA nephropathy.UBS remains confident the degraders could differentiate from competition, but noted that the primary completion dates are January 2028 for generalized dystonia and September 2028 for IgA nephropathy.The firm also noted Biohaven's partial clinical hold on BHV-7000 requires additional nonclinical studies related to a metabolite observed in rodents and pauses enrollment in the RISE-2 study. The partial hold does not affect RISE-3, which is fully enrolled, with UBS expecting data in November.UBS reiterated its neutral rating and $11 price target on Biohaven.Price: 13.99, Change: +0.10, Percent Change: +0.72","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2668922511","isCrawlerRequest":true}